51. Effects of Candesartan and Lisinopril on the Fibrinolytic System in Hypertensive Patients
- Author
-
Andreas Bur, Christian Woisetschlaeger, Anton N. Laggner, Michael M. Hirschl, and Ulla Derhaschnig
- Subjects
Adult ,Male ,medicine.medical_specialty ,Angiotensin receptor ,Endocrinology, Diabetes and Metabolism ,medicine.medical_treatment ,Tetrazoles ,Angiotensin-Converting Enzyme Inhibitors ,Blood Pressure ,Tissue plasminogen activator ,chemistry.chemical_compound ,Double-Blind Method ,Lisinopril ,Internal medicine ,Plasminogen Activator Inhibitor 1 ,Fibrinolysis ,Internal Medicine ,medicine ,Humans ,Prospective Studies ,Antihypertensive Agents ,biology ,business.industry ,Biphenyl Compounds ,Middle Aged ,Original Papers ,Candesartan ,Blood pressure ,Endocrinology ,chemistry ,Enzyme inhibitor ,Tissue Plasminogen Activator ,Plasminogen activator inhibitor-1 ,Hypertension ,biology.protein ,Benzimidazoles ,Female ,Cardiology and Cardiovascular Medicine ,business ,Angiotensin II Type 1 Receptor Blockers ,medicine.drug - Abstract
The effects of the angiotensin II receptor blocker candesartan and the angiotensin‐converting enzyme inhibitor lisinopril on the fibrinolytic system were investigated in a double‐blinded, prospective, randomized study. Seventy‐seven hypertensive patients taking candesartan (n=41) and lisinopril (n=36) with a systolic blood pressure >130 mm Hg and/or a diastolic blood pressure >80 mm Hg obtained by 24‐hour ambulatory blood pressure measurement were included in the study. Blood pressure, plasminogen activator inhibitor 1 (PAI‐1), tissue plasminogen activator (tPA), and the molar ratio of PAI‐1/tPA were determined before treatment and 6 weeks later. Blood pressure decreased in both groups (candesartan, 155/85 mm Hg to 140/84 mm Hg; P
- Published
- 2007